Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients

• Published in: Haematologica (Roma) Vol. 107; no. 3; pp. 615 - 624
• Main Authors: Bloehdorn, Johannes, Krzykalla, Julia, Holzmann, Karlheinz, Gerhardinger, Andreas, Jebaraj, Billy Michael Chelliah, Bahlo, Jasmin, Humphrey, Kathryn, Tausch, Eugen, Robrecht, Sandra, Mertens, Daniel, Schneider, Christof, Fischer, Kirsten, Hallek, Michael, Döhner, Hartmut, Benner, Axel, Stilgenbauer, Stephan
• Format: Journal Article
• Language: English
• Published: Italy Fondazione Ferrata Storti 01.03.2022; Ferrata Storti Foundation
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cyclophosphamide - therapeutic use; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Mutation; Prognosis; Rituximab - therapeutic use

Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) can induce long-term remissions in patients with chronic lymphocytic leukemia. Treatment efficacy with Bruton's tyrosine kinase inhibitors was found similar to FCR in untreated chronic lymphocytic leukemia patients with a...